Inflammatory profile of convalescent plasma to treat COVID: Impact of amotosalen/UVA pathogen reduction technology [PDF]
Frontiers in Immunology, 2022 Blood products in therapeutic transfusion are now commonly acknowledged to contain biologically active constituents during the processes of preparation. In the midst of a worldwide COVID-19 pandemic, preliminary evidence suggests that convalescent plasma
Fabrice Cognasse +27 more
doaj +2 more sources
Platelets treated with pathogen reduction technology: current status and future direction [version 1; peer review: 2 approved] [PDF]
F1000Research, 2020 Allogeneic platelets collected for transfusion treated with pathogen reduction technology (PRT), which has been available in some countries for more than a decade, are now increasingly available in the United States (US).
Wen Lu, Mark Fung
doaj +2 more sources
Journal of Photochemistry and Photobiology, 2021 With the rapid evolving of emerging pathogens and residual risk of bacterial contamination in platelets, they continue to pose a constant threat to the safety of blood supply despite effort implemented to mitigate such risk via conventional measures and ...
Hong Liu, Xun Wang
doaj +3 more sources
Mirasol pathogen reduction technology treatment of human whole blood does not induce acute lung injury in mice. [PDF]
PLoS ONE, 2017 In resource-limited settings and in the military theater, fresh human whole blood is commonly transfused, but infectious risks are a concern. Sophisticated molecular testing for potential infectious agents in the whole blood is often unavailable.
Beñat Mallavia +4 more
doaj +2 more sources
Whole blood pathogen reduction technology and blood safety in sub-Saharan Africa: A systematic review with regional discussion [PDF]
African Journal of Laboratory Medicine, 2016 Background: Despite vast improvements in transfusion services in sub-Saharan Africa over the last decade, there remain serious concerns on the safety and adequacy of the blood supply across the region.
Asa'ah Nkohkwo +4 more
doaj +2 more sources
Transfusion of Human Platelets Treated with Mirasol Pathogen Reduction Technology Does Not Induce Acute Lung Injury in Mice. [PDF]
PLoS ONE, 2015 Pathogen reduction technology (PRT) has been developed in an effort to make the blood supply safer, but there is controversy as to whether it may induce structural or functional changes to platelets that could lead to acute lung injury after transfusion.
Axelle Caudrillier +4 more
doaj +2 more sources
Platelets, 2019 Platelet concentrates (PCs) represent a blood transfusion product with a major concern for safety as their storage temperature (20–24°C) allows bacterial growth, and their maximum storage time period (less than a week) precludes complete microbiological ...
Vishal Salunkhe +8 more
doaj +2 more sources
Pathogen Reduction of Transfused Blood Components—The End of the Beginning Rather than the Beginning of the End [PDF]
PathogensTherapeutics derived from donated blood or its constituents are classifiable into blood components and plasma derivatives. The latter are defined as medicines/drugs/pharmaceuticals produced from the industrial fractionation of thousands of pooled plasma ...
Albert Farrugia +3 more
doaj +2 more sources
Elevated plasma testosterone concentrations from males on testosterone replacement therapy are mitigated with pathogen reduction technology. [PDF]
TransfusionGreenwall B, Reeder K, Anani W.
europepmc +2 more sources
Pathogens, 2022 In this systematic review, we evaluate the efficacy and safety of blood components treated with pathogen reduction technologies (PRTs). We searched the Medline, Embase, Scopus, Ovid, and Cochrane Library to identify RCTs evaluating PRTs.
Ilaria Pati +4 more
doaj +1 more source